全文获取类型
收费全文 | 78088篇 |
免费 | 7468篇 |
国内免费 | 4845篇 |
专业分类
耳鼻咽喉 | 581篇 |
儿科学 | 1024篇 |
妇产科学 | 1241篇 |
基础医学 | 9298篇 |
口腔科学 | 1557篇 |
临床医学 | 9249篇 |
内科学 | 11897篇 |
皮肤病学 | 822篇 |
神经病学 | 4313篇 |
特种医学 | 2811篇 |
外国民族医学 | 32篇 |
外科学 | 7700篇 |
综合类 | 12880篇 |
一般理论 | 12篇 |
预防医学 | 5271篇 |
眼科学 | 2088篇 |
药学 | 8568篇 |
62篇 | |
中国医学 | 4392篇 |
肿瘤学 | 6603篇 |
出版年
2024年 | 69篇 |
2023年 | 1194篇 |
2022年 | 1942篇 |
2021年 | 3288篇 |
2020年 | 3207篇 |
2019年 | 3557篇 |
2018年 | 2322篇 |
2017年 | 2442篇 |
2016年 | 2043篇 |
2015年 | 3387篇 |
2014年 | 4280篇 |
2013年 | 4006篇 |
2012年 | 6076篇 |
2011年 | 6396篇 |
2010年 | 4166篇 |
2009年 | 3286篇 |
2008年 | 4446篇 |
2007年 | 4281篇 |
2006年 | 3875篇 |
2005年 | 3809篇 |
2004年 | 2751篇 |
2003年 | 2493篇 |
2002年 | 2223篇 |
2001年 | 1819篇 |
2000年 | 1894篇 |
1999年 | 1980篇 |
1998年 | 1246篇 |
1997年 | 1230篇 |
1996年 | 962篇 |
1995年 | 949篇 |
1994年 | 780篇 |
1993年 | 487篇 |
1992年 | 562篇 |
1991年 | 511篇 |
1990年 | 430篇 |
1989年 | 387篇 |
1988年 | 301篇 |
1987年 | 299篇 |
1986年 | 233篇 |
1985年 | 184篇 |
1984年 | 119篇 |
1983年 | 82篇 |
1982年 | 58篇 |
1981年 | 46篇 |
1980年 | 33篇 |
1979年 | 44篇 |
1978年 | 18篇 |
1974年 | 17篇 |
1972年 | 16篇 |
1966年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Tianshu Liu Yuxian Bai Xiaoyan Lin Wei Li Jufeng Wang Xiaochun Zhang Hongming Pan Chunmei Bai Li Bai Ying Cheng Jingdong Zhang Haijun Zhong Yi Ba Wenwei Hu Ruihua Xu Weijian Guo Shukui Qin Nong Yang Jianwei Lu Kohei Shitara Ming Lei Mingshun Li Nicole Bao Tian Chen Lin Shen 《International journal of cancer. Journal international du cancer》2023,152(4):749-760
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC. 相似文献
2.
Shuang Lu Hong Sun Kim Yubo Cao Karan Bedi Lili Zhao Ishwarya Venkata Narayanan Brian Magnuson Yumei Gu Jing Yang Zhujun Yi Sepideh Babaniamansour Sargis Shameon Chang Xu Michelle T. Paulsen Ping Qiu Sivakumar Jeyarajan Mats Ljungman Dafydd Thomas Yali Dou Howard Crawford Marina Pasca di Magliano Kai Ge Bo Yang Jiaqi Shi 《International journal of cancer. Journal international du cancer》2023,153(3):552-570
3.
Qi Zhang Ye Zhou Lijie Song Weijia Fang Meng Qiu Yanhong Gu Yang Yang Jingdong Zhang Jing Liu Jian Li Ming Lu Tianxiao Gong Xin Wang Yan Li Jun Yang Yingjiang Ye Lin Shen 《International journal of cancer. Journal international du cancer》2023,153(11):1885-1893
Formal multidisciplinary team (MDT) discussions in clinical practice require time and space but have unclear survival benefits for advanced gastrointestinal cancer patients. Our study aimed to investigate the long-term survival of patients with advanced gastrointestinal cancer after MDT decision. From June 2017 to June 2019, continuous MDT discussions on advanced gastrointestinal cancer were conducted in 13 medical centers in China. MDT decisions and actual treatment received by patients were prospectively recorded. The primary endpoint was the difference in overall survival (OS) between patients in the MDT decision implementation and nonimplementation groups. The secondary endpoints included the implementation rate of MDT decisions and subgroup survival analysis. A total of 461 MDT decisions of 455 patients were included in our study. The implementation rate of MDT decisions was 85.7%. Previous treatment had an impact on MDT decision-making. The OS was 24.0 months and 17.0 months in the implementation and nonimplementation groups, respectively. The implementation of MDT decisions significantly reduced the risk of death in multivariate analyses (hazard ratio = 0.518; 95% confidence interval: 0.304-0.884, P = .016). Subgroup analysis showed a significant difference in survival of patients with colorectal cancer, but not in survival of patients with gastric cancer. The rate of secondary MDT discussion was only 5.6% among patients who the MDT decisions were discontinued due to changes in their condition. MDT discussion can prolong the OS of patients with advanced gastrointestinal cancer, especially those with colorectal cancer. Timely scheduling of the subsequent MDT discussion is necessary when the disease condition changes. 相似文献
4.
Qiangsheng He Chongfei Huang Xiwen Qin Yuanyuan Yu Di Tang Junjie Huang Zi Chong Kuo Yuyao Ling Deli Mao Bin Xia Wenjing Li Kuiqing Lu Man Yang Yulong He Wenbo Meng Jinqiu Yuan Yihang Pan 《International journal of cancer. Journal international du cancer》2023,153(5):942-949
Recent epidemiological studies suggested that proton pump inhibitor (PPI) use was associated with an increased risk of biliary tract cancer (BTC), however, confounders were not adequately controlled. Our study aimed to evaluate PPI use and subsequent risk of BTC and its subtypes in three well-established cohorts. We conducted a pooled analysis of the subjects free of cancers in UK Biobank (n = 463 643), Nurses' Health Study (NHS, n = 80 235) and NHS II (n = 95 869). Propensity score weighted Cox models were used to estimate marginal HRs of PPIs use on BTC risk, accounting for potential confounders. We documented 284 BTC cases in UK Biobank (median follow-up: 7.6 years), and 91 cases in NHS and NHS II cohorts (median follow-up: 15.8 years). In UK biobank, PPI users had a 96% higher risk of BTC compared to nonusers in crude model (HR 1.96, 95% CI 1.44-2.66), but the effect was attenuated to null after adjusting for potential confounders (HR 0.95, 95% CI 0.60-1.49). PPI use was not associated with risk of BTC in the pooled analysis of three cohorts (HR 0.93, 95% CI 0.60-1.43). We also observed no associations between PPI use with risk of intrahepatic (HR 1.00, 95% CI 0.49-2.04), extrahepatic bile duct (HR 1.09, 95% CI 0.52-2.27) and gallbladder cancers (HR 0.66, 95% CI 0.26-1.66) in UK Biobank. In summary, regular use of PPIs was not associated with the risk of BTC and its subtypes. 相似文献
5.
目的探讨妊娠合并肺动脉高压患者剖宫产围产期并发症的危险因素。方法该研究为病例对照研究。回顾性纳入山东大学齐鲁医院、山东第一医科大学附属省立医院、山东省千佛山医院和青岛大学附属医院2010年5月至2020年5月妊娠合并肺动脉高压患者。根据是否发生剖宫产围产期并发症分为并发症组和对照组。收集患者的一般临床资料和辅助检查结果, 记录患者发生围产期并发症的情况。围产期并发症包括心功能恶化、新发心律失常、心脏骤停、术后42 d内全因死亡、产后出血及血栓事件。采用多因素logistic回归模型分析妊娠合并肺动脉高压患者剖宫产围产期并发症的危险因素。结果研究纳入患者167例, 年龄28(24, 32)岁, 其中并发症组47例, 对照组120例。两组患者年龄, 孕周, 初产妇、存在心内分流及接受靶向药物治疗者比例, 左、右心室舒张末期内径差异均无统计学意义(P均>0.05)。与对照组比较, 并发症组患者特发性肺动脉高压者比例较高(P=0.001)、接受全身麻醉的比例较高(P=0.001)、超声心动图估测的肺动脉收缩压较高(P<0.001)、术前世界卫生组织(WHO)功能Ⅲ/Ⅳ级者比例较高(... 相似文献
6.
目的观察老年冠心病患者移动健康管理模式的构建, 并进行实证研究。方法选取2019年1月至2021年1月于河南省人民医院接受治疗的86例老年冠心病患者, 随机数字表法分为两组, 每组各43例, 对照组实施常规干预, 观察组在常规干预基础上应用移动健康管理模式进行干预, 两组均干预3个月, 评估患者心绞痛情况、再入院危险因素控制评价指标达标情况[低密度脂蛋白胆固醇(LDL-C)、静息心率、收缩压、舒张压];于干预前、干预3个月, 评估患者自护能力。结果观察组心绞痛发作次数少于对照组[(0.53±0.18)次/周和(0.64±0.15)次/周, t=3.079, P=0.003], 持续时间短于对照组[(2.72±0.40)min和(3.06±0.55)min, t=3.278, P=0.002];观察组再入院危险因素LDL-C(90.7%比72.1%, χ2=4.914, P=0.027)、静息心率(95.4%比81.4%, χ2=4.074, P=0.044)、收缩压(86.1%比60.5%, χ2=7.182, P=0.007)、舒张压达标率(88.4%比67.4%, χ2=5.472... 相似文献
7.
Folayan Morenike Oluwatoyin Ibigbami Olanrewaju Brown Brandon El Tantawi Maha Uzochukwu Benjamin Ezechi Oliver C. Aly Nourhan M. Abeldaño Giuliana Florencia Ara Eshrat Ayanore Martin Amogre Ayoola Oluwagbemiga O. Osamika Bamidele Emmanuel Ellakany Passent Gaffar Balgis Idigbe Ifeoma Ishabiyi Anthonia Omotola Jafer Mohammed Khan Abeedha Tu-Allah Khalid Zumama Lawal Folake Barakat Lusher Joanne Nzimande Ntombifuthi P. Popoola Bamidele Olubukola Quadri Mir Faeq Ali Rashwan Maher Roque Mark Shamala Anas Al-Tammemi Ala’a B. Yousaf Muhammad Abrar Abeldaño Zuñiga Roberto Ariel Okeibunor Joseph Chukwudi Nguyen Annie Lu 《AIDS and behavior》2022,26(3):739-751
AIDS and Behavior - The aim of the study was to assess if there were significant differences in the adoption of COVID-19 risk preventive behaviors and experience of food insecurity by people living... 相似文献
8.
Johnson Laura M. Green Harold D. Lu Minggen Stockman Jamila K. Felsher Marisa Roth Alexis M. Wagner Karla D. 《AIDS and behavior》2022,26(9):2866-2880
AIDS and Behavior - Pre-Exposure Prophylaxis (PrEP) health campaigns invite women to talk with their provider, partner, and peers about PrEP, though they do not offer specific guidance about who... 相似文献
9.
目的探讨霉菌性外耳道炎患者接受耳内镜下外耳道冲洗联合酮康唑纱条治疗的临床效果。方法选取2018年2月至2019年3月本院收治的89例霉菌性外耳道炎患者,分为对照组(n=44)与观察组(n=45)。两组均进行耳内镜下外耳道冲洗,对照组在此基础上联合复发水杨酸滴耳治疗,观察组在外耳道冲洗基础上加用酮康唑纱条治疗。比较两组临床疗效和复发率。结果观察组治疗总有效率(93.33%)高于对照组(72.73%),差异有统计学意义(P<0.05);随访8个月,观察组复发率(8.89%)低于对照组(25.00%),差异有统计学意义(P<0.05)。结论耳内镜下外耳道冲洗联合酮康唑纱条治疗霉菌性外耳道炎患者有利于提高治疗有效率,降低疾病复发率。 相似文献